United States

Securities and Exchange Commission, Washington, D.C. 20549

Schedule 13G

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

BioXcel Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

09075P105

(CUSIP Number)

December 31, 2018

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o Rule 13d-1(b)

o Rule 13d-1(c)

x Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(*) Based on 20,182,382 shares of Common Stock of the Issuer outstanding as of March 9, 2020 (as reported by the Issuer in its Form 10-K filed with the Securities Exchange Commission on March 9, 2020).

(*) Based on 20,182,382 shares of Common Stock of the Issuer outstanding as of March 9, 2020 (as reported by the Issuer in its Form 10-K filed with the Securities Exchange Commission on March 9, 2020).

(*) Based on 20,182,382 shares of Common Stock of the Issuer outstanding as of March 9, 2020 (as reported by the Issuer in its Form 10-K filed with the Securities Exchange Commission on March 9, 2020).

(*) Based on 20,182,382 shares of Common Stock of the Issuer outstanding as of March 9, 2020 (as reported by the Issuer in its Form 10-K filed with the Securities Exchange Commission on March 9, 2020).

Explanatory Note

This Amendment No. 1 to Schedule 13G is being filed to correct the inadvertent omission of Vimal Mehta as a Reporting Person from the Schedule 13G filed on February 14, 2019. In addition, effective April 23, 2020 at 3:00 p.m. (the “Effective Time”), BioXcel Corporation, a Delaware corporation, merged with and into BioXcel LLC, a Delaware limited liability company, in accordance with the terms of an Agreement and Plan of Merger, dated April 23, 2020 (the “Agreement”) (the “Reorganization”). Pursuant to the Agreement and as result of the Reorganization, at the Effective Time, each of the outstanding shares of common stock of BioXcel Corporation was converted into and exchanged for one newly issued share of the common stock of BioXcel Holdings, Inc., a Delaware corporation, and BioXcel LLC became a subsidiary of BioXcel Holdings, Inc.

Item 1(a) Name of issuer:

BioXcel Therapeutics, Inc.

Item 1(b) Address of issuer’s principal executive offices:

The Issuer’s principal executive offices are located at 555 Long Wharf Drive, New Haven, CT 06511.

2(a) Name of person filing:

This statement is filed by:

(i) BioXcel LLC;

(ii) BioXcel Holdings, Inc.;

(iii) Krishnan Nandabalan (“Mr. Nandabalan”); and

(iv) Vimal Mehta (“Mr. Mehta”).

The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.” Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.

The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.

2(b) Address or principal business office or, if none, residence:

The principal business address of each of the Reporting Persons is 2614 Boston Post Road, Suite #33B, Guilford, CT 06437.

2(c) Citizenship:

BioXcel LLC is a limited liability company organized under the laws of the State of Delaware. BioXcel Holdings, Inc. is a corporation organized under the laws of the State of Delaware. Each of Mr. Nandabalan and Mr. Mehta is a citizen of the United States.

2(d) Title of class of securities:

Common Stock, par value $0.001 per share (the “Common Stock”)

2(e) CUSIP No.:

09075P105

Item 3 If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable

Item 4. Ownership.

The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based on 20,182,382 outstanding shares of Common Stock, as reported in the Issuer’s Form 10-K filed on March 9, 2020.

As of the date hereof, BioXcel LLC is the record holder of 9,180,000 shares of Common Stock. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. Each of Mr. Nandabalan and Mr. Mehta is a manager and officer of BioXcel LLC, and a director, officer and shareholder of BioXcel Holdings, Inc. As such, each of Mr. Nandabalan and Mr. Mehta may be deemed to beneficially own the securities held of record by BioXcel LLC.  Each of them disclaims any such beneficial ownership.

In addition, Mr. Nandabalan may be deemed to beneficially own 480,622 shares of Common Stock, which includes 1,000 shares of Common stock and 479,622 shares of Common Stock issuable upon exercise of employee stock options that are currently exercisable or may be exercised within 60 days of the date hereof. Mr. Mehta may be deemed to beneficially own 577,805 shares of Common Stock, which includes 9,957 shares of Common stock and 567,848 shares of Common Stock issuable upon exercise of employee stock options that are currently exercisable or may be exercised within 60 days of the date hereof.

Item 5. Ownership of 5 Percent or Less of a Class.

Not applicable

Item 6. Ownership of More than 5 Percent on Behalf of Another Person.

Not applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable

Item 8. Identification and Classification of Members of the Group.

Not applicable

Item 9. Notice of Dissolution of Group.

Not applicable

Item 10. Certifications.

Not applicable

List of Exhibits

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated May 14, 2020.

EXHIBIT 1

JOINT FILING AGREEMENT

PURSUANT TO RULE 13d-1(k)

The undersigned acknowledge and agree that the foregoing amendment to Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. The undersigned hereby further agree that this Joint Filing Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original, but all of which counterparts shall together constitute one and the same instrument.

Date: May 14, 2020